PortfoliosLab logoPortfoliosLab logo
ALNY vs. AGX
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

ALNY vs. AGX - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Alnylam Pharmaceuticals, Inc. (ALNY) and Argan, Inc. (AGX). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, ALNY achieves a -48.32% return, which is significantly lower than AGX's 82.59% return. Over the past 10 years, ALNY has underperformed AGX with an annualized return of 11.28%, while AGX has yielded a comparatively higher 31.98% annualized return.


ALNY

1D
0.02%
1M
-34.29%
6M
-39.21%
YTD
-48.32%
1Y
-48.85%
3Y*
2.82%
5Y*
2.81%
10Y*
11.28%
ALL TIME*
17.20%

AGX

1D
-1.63%
1M
-19.15%
6M
64.61%
YTD
82.59%
1Y
154.43%
3Y*
149.27%
5Y*
69.22%
10Y*
31.98%
ALL TIME*
29.36%
*Multi-year figures are annualized to reflect compound growth (CAGR)

Liquidity Comparison


PositionAvg. Volume Value (2W)Avg. Volume Value (1M)Avg. Volume Value (3M)
$205.92M$203.49M$229.51M
$567.18M$557.43M$409.61M

ALNY vs. AGX - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
ALNY
Alnylam Pharmaceuticals, Inc.
-48.32%68.99%22.94%-19.46%40.14%30.48%12.85%57.96%-42.61%239.34%
AGX
Argan, Inc.
82.59%130.61%198.31%30.24%-2.01%-11.64%19.15%8.62%-14.32%-34.26%

Correlation

The correlation between ALNY and AGX is 0.08, meaning there was essentially no consistent relationship between their historical price movements. Each responded to its own set of market drivers.


Correlation
Correlation (1Y)
Focuses on recent behavior, but can change the most.

0.08

Correlation (3Y)
Balances recent behavior with more history.

0.10

Correlation (5Y)
Shows whether the relationship held over a longer period.

0.14

Correlation (10Y)
Provides a long-term view across more market conditions.

0.13

Correlation (All Time)
Calculated using the full available price history since Jun 1, 2004

0.17

Fundamentals

Market Cap

ALNY:

$27.44B

AGX:

$8.00B

EPS

ALNY:

$5.88

AGX:

$11.38

PE Ratio

ALNY:

34.98

AGX:

50.15

PS Ratio

ALNY:

5.88

AGX:

7.76

PB Ratio

ALNY:

20.98

AGX:

17.10

Total Revenue (TTM)

ALNY:

$4.80B

AGX:

$1.04B

Gross Profit (TTM)

ALNY:

$1.88B

AGX:

$217.93M

EBITDA (TTM)

ALNY:

$822.65M

AGX:

$163.99M

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

ALNY vs. AGX — Risk / Return Rank

Compare historical risk-adjusted metric ranks over the past 12 months.

ALNY
ALNY Risk / Return Rank: 66
Overall Rank
ALNY Sharpe Ratio Rank: 44
Sharpe Ratio Rank
ALNY Sortino Ratio Rank: 88
Sortino Ratio Rank
ALNY Omega Ratio Rank: 55
Omega Ratio Rank
ALNY Calmar Ratio Rank: 1212
Calmar Ratio Rank
ALNY Martin Ratio Rank: 33
Martin Ratio Rank

AGX
AGX Risk / Return Rank: 8989
Overall Rank
AGX Sharpe Ratio Rank: 8888
Sharpe Ratio Rank
AGX Sortino Ratio Rank: 8888
Sortino Ratio Rank
AGX Omega Ratio Rank: 8585
Omega Ratio Rank
AGX Calmar Ratio Rank: 9090
Calmar Ratio Rank
AGX Martin Ratio Rank: 9393
Martin Ratio Rank
The rank (0–100) uses a weighted average of the Sharpe, Sortino, Omega, Calmar, and Martin percentile ranks for the trailing 12 months. Higher means stronger historical risk-adjusted performance within the peer group.

ALNY vs. AGX - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Alnylam Pharmaceuticals, Inc. (ALNY) and Argan, Inc. (AGX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.


ALNYAGXDifference
Sharpe ratioReturn per unit of total volatility

-2.76

Sortino ratioReturn per unit of downside risk

-3.94

Omega ratioGain probability vs. loss probability

0.78

1.31

-0.53

Calmar ratioReturn relative to maximum drawdown

-0.82

3.52

-4.34

Martin ratioReturn relative to average drawdown

-1.68

12.03

-13.72

ALNY vs. AGX - Sharpe Ratio Comparison

The current ALNY Sharpe Ratio is -1.07, which is lower than the AGX Sharpe Ratio of 1.70. The chart below compares the historical Sharpe Ratios of ALNY and AGX, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Drawdowns

ALNY vs. AGX - Drawdown Comparison

The maximum ALNY drawdown since its inception was -83.58%, smaller than the maximum AGX drawdown of -94.37%. Use the drawdown chart below to compare losses from any high point for ALNY and AGX.


Loading charts...

Drawdown Indicators


ALNYAGXDifference

Max Drawdown

Largest peak-to-trough decline

-83.58%

-94.37%

+10.79%

Max Drawdown (1Y)

Largest decline over 1 year

-58.17%

-38.29%

-19.88%

Max Drawdown (3Y)

Largest decline over 3 years

-58.17%

-43.75%

-14.42%

Max Drawdown (5Y)

Largest decline over 5 years

-58.17%

-43.75%

-14.42%

Max Drawdown (10Y)

Largest decline over 10 years

-59.95%

-54.61%

-5.34%

Current Drawdown

Current decline from peak

-58.16%

-28.51%

-29.65%

Average Drawdown

Average peak-to-trough decline

-30.66%

-48.20%

+17.54%

Ulcer Index

Depth and duration of drawdowns from previous peaks

28.31%

11.32%

+16.99%

Volatility

ALNY vs. AGX - Volatility Comparison

Alnylam Pharmaceuticals, Inc. (ALNY) has a higher volatility of 35.07% compared to Argan, Inc. (AGX) at 29.09%. This indicates that ALNY's price experiences larger fluctuations and is considered to be riskier than AGX based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


ALNYAGXDifference

Volatility (1M)

Calculated over the trailing 1-month period

35.07%

29.09%

+5.98%

Volatility (6M)

Calculated over the trailing 6-month period

41.89%

59.13%

-17.24%

Volatility (1Y)

Calculated over the trailing 1-year period

47.33%

79.49%

-32.16%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

50.53%

52.94%

-2.41%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

54.28%

46.95%

+7.33%

Dividends

ALNY vs. AGX - Dividend Comparison

ALNY has not paid dividends to shareholders, while AGX's dividend yield for the trailing twelve months is around 0.35%.


PositionTTM20252024202320222021202020192018201720162015
AGX
Argan, Inc.
0.35%0.52%0.93%2.24%2.71%1.94%7.31%2.49%1.98%4.44%1.42%2.16%
ALNY
Alnylam Pharmaceuticals, Inc.
0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%0.00%

Financials

ALNY vs. AGX - Financials Comparison

This section allows you to compare key financial metrics between Alnylam Pharmaceuticals, Inc. and Argan, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


Values in USD except per share items

ALNY vs. AGX - Profitability Comparison

The chart below illustrates the profitability comparison between Alnylam Pharmaceuticals, Inc. and Argan, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

ALNY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Alnylam Pharmaceuticals, Inc. reported a gross profit of -956.05M and revenue of 1.29B. Therefore, the gross margin over that period was -74.1%.

AGX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Aug 2026, Argan, Inc. reported a gross profit of 61.11M and revenue of 290.95M. Therefore, the gross margin over that period was 21.0%.

ALNY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Alnylam Pharmaceuticals, Inc. reported an operating income of 231.44M and revenue of 1.29B, resulting in an operating margin of 17.9%.

AGX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Aug 2026, Argan, Inc. reported an operating income of 45.40M and revenue of 290.95M, resulting in an operating margin of 15.6%.

ALNY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Alnylam Pharmaceuticals, Inc. reported a net income of 164.49M and revenue of 1.29B, resulting in a net margin of 12.7%.

AGX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Aug 2026, Argan, Inc. reported a net income of 46.06M and revenue of 290.95M, resulting in a net margin of 15.8%.


Frequently Asked Questions


ALNY and AGX have a correlation of 0.08, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

ALNY has higher volatility (35.07%) compared to AGX (29.09%). In terms of maximum drawdown, ALNY dropped -83.58% vs AGX's -94.37%.

AGX currently has the higher Sharpe Ratio (1.70 vs -1.07), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for ALNY and AGX

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer